ACH
ICPT

ArrowMark Colorado Holdings’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

ArrowMark Colorado Holdings’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-1,242
Closed -$410K – 363
2014
Q1 		$410K Buy
+1,242
New +$419K 0.01% 250

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

ArrowMark Colorado Holdings's ICPT Position: Q2 2014 in Review

ArrowMark Colorado Holdings sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q2 2014, closing a stake of 1,242 shares — an estimated $410K sold.

ArrowMark Colorado Holdings first reported a position in ICPT in Q1 2014 and held it in 1 quarter. The position peaked at $410K in Q1 2014. 167 funds tracked by Wall St. Rank hold ICPT as of Q2 2014.

  • ArrowMark Colorado Holdings reported no remaining Intercept Pharmaceuticals, Inc. position as of Q2 2014 after selling out during the quarter.
  • ArrowMark Colorado Holdings sold 1,242 Intercept Pharmaceuticals, Inc. shares in Q2 2014, an estimated $410K.
  • ArrowMark Colorado Holdings first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2014 and held it in 1 quarter.
  • ArrowMark Colorado Holdings's Intercept Pharmaceuticals, Inc. position peaked at $410K in Q1 2014.
  • 167 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q2 2014.

Based on ArrowMark Colorado Holdings's 13F filing for Q2 2014, filed 14 Aug 2014.